Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/43140| Title: | Edoxaban and/or colchicine in outpatients with COVID-19: rationale and design of the CONVINCE trial | Authors: | Landi, A Morici, N VRANCKX, Pascal Frigoli, E Bonacchini, L Omazzi, B Tresoldi, M Camponovo, C Moccetti, T Valgimigli, M |
Issue Date: | 2023 | Publisher: | LIPPINCOTT WILLIAMS & WILKINS | Source: | JOURNAL OF CARDIOVASCULAR MEDICINE, 24 (12) , p. 920 -930 | Abstract: | An excessive inflammatory response and a hypercoagulable state are not infrequent in patients with coronavirus disease-2019 (COVID-19) and are associated with adverse clinical outcomes. However, the optimal treatment strategy for COVID-19 patients managed in the out-of-hospital setting is still uncertain. | Keywords: | anticoagulant therapy;anti-inflammatory therapy;colchicine;COVID-19;edoxaban;SARS-CoV-2 | Document URI: | http://hdl.handle.net/1942/43140 | ISSN: | 1558-2027 | e-ISSN: | 1558-2035 | DOI: | 10.2459/JCM.0000000000001556 | ISI #: | 001102568100009 | Rights: | 2023 Italian Federation of Cardiology - I.F.C. All rights reserved. | Category: | A1 | Type: | Journal Contribution |
| Appears in Collections: | Research publications |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| bb.pdf | Peer-reviewed author version | 1.05 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.